OncoSil Medical has secured $5.6 million in fresh capital from its three biggest institutional shareholders, giving the Sydney-based medical device company the financial firepower to launch its targeted radiation therapy in the United States and Australia after years of regulatory work.

Emyria is on the verge of opening its first clinic in Sydney, marking the company's entry into New South Wales and extending its national network of intensive mental health services into Australia's most populous state.

Telix Pharmaceuticals has completed enrolment in its pivotal BiPASS trial, moving the Australian company closer to testing whether its gallium-based PSMA PET imaging agents can help determine which men with suspected prostate cancer need a biopsy in the first place.

OncoSil Medical has moved to secure a Medicare reimbursement pathway for its targeted internal radiation device in the United States, following the Food and Drug Administration’s humanitarian approval of the treatment for a rare and difficult-to-treat form of bile duct cancer.

Prescient Therapeutics has reached an important enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December.

ENA Respiratory has welcomed $2.98 million in funding from Biointelect Venturer to support its first Australian study of INNA-051 in adults with asthma, expanding the clinical program for a once-weekly nasal spray intended to strengthen the body’s early defences against common respiratory viruses.

Vitrafy Life Sciences has secured its first foothold in the United States cell and gene therapy market through an agreement with Charter Medical to install its cryopreservation technology in the North Carolina company’s Innovation Hub.

Six Australian companies developing vaccines, antiviral treatments, and vaccine-production technologies will share $10.48 million in Biointelect Venture's first funding round.

Melbourne company Cartherics is joining forces with the Zucker Institute at the Medical University of South Carolina to investigate whether a novel antibody can strengthen next-generation immune cell therapies for solid tumours and endometriosis.

Percheron Therapeutics has secured firm commitments for a $2.3 million institutional placement, providing what the company says is full funding for a new clinical trial of its lead drug candidate, HMBD-002, in acute myeloid leukaemia and myelodysplastic syndrome.

Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as it prepares to begin its planned Phase 3 clinical trial of ATH434 for multiple system atrophy.

Tetratherix has exported its first commercial shipment of Tetramatrix polymer to the United States, marking the start of product revenue for the ASX-listed company’s Precision Medicine franchise.

Avecho Biotechnology has restarted recruitment for the final stage of its pivotal Phase 3 trial of a cannabidiol capsule designed to treat insomnia, after an independent review found the study could continue without increasing its planned sample size.

Genetic Signatures and Microba Life Sciences have announced they are in preliminary discussions about a potential merger that would combine rapid infectious disease testing with gut microbiome profiling and create a larger ASX-listed diagnostics business.

Mesoblast reported a sharp rise in revenue as sales of its cell therapy, Ryoncil, accelerated in the United States, while its chronic low back pain program moved closer to a decisive clinical readout.

Neuren Pharmaceuticals has announced it will begin paying dividends to shareholders for the first time, following a sharp increase in royalty income from its Rett syndrome treatment, DAYBUE (trofinetide).

Chief executive Cheryl Maley said the year brought advances in the company’s lead radiopharmaceutical program, new strategic partnerships, and further validation of DEP technology's potential in targeted cancer treatment.